Abbvie Inc.

Adivaraha Jayasankar

Geoff G Zhang

Yi Gao

Eric Allen Schmitt

Nancy E Sever

Ping Tong

Ulrich Westedt

Ute Lander

Harald Hach

Colleen Garrett

Constanze Obermiller

Huailiang Wu

Marius Naris

Regina Reul

Ameesha Patel

Katrin Schneider

David Beno

Hao Hou

Michael Simon

Benedikt Steitz

Samuel Kyeremateng

Katharina Asmus

Thomas Mueller

Donghua Zhu

Michael Siimon

The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

Solid pharmaceutical compositions for treating HCV

A pharmaceutical product comprising at least one phenyl uracil-based pharmaceutically active agent or an agent of related structural type and processes for obtaining such product.

Formulations of phenyl uracil compounds

Growing community of inventors

Naperville, IL, United States of America

Adivaraha Jayasankar